See more : Morguard Corporation (MRCBF) Income Statement Analysis – Financial Results
Complete financial analysis of Aura Biosciences, Inc. (AURA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aura Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Southeast Cement Corporation (1110.TW) Income Statement Analysis – Financial Results
- Kensington Capital Acquisition Corp. V (KCGI-UN) Income Statement Analysis – Financial Results
- Costa Group Holdings Limited (CGC.AX) Income Statement Analysis – Financial Results
- RenaissanceRe Holdings Ltd. (RNR-PE) Income Statement Analysis – Financial Results
- Aimei Health Technology Co., Ltd Unit (AFJKU) Income Statement Analysis – Financial Results
Aura Biosciences, Inc. (AURA)
About Aura Biosciences, Inc.
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.30M | 1.18M | 835.00K | 831.00K | 509.00K |
| Gross Profit | -1.30M | -1.18M | -835.00K | -831.00K | -509.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 65.23M | 42.24M | 25.16M | 18.04M | 19.62M |
| General & Administrative | 19.76M | 18.06M | 10.09M | 4.16M | 4.52M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.76M | 18.06M | 10.09M | 4.16M | 4.52M |
| Other Expenses | 0.00 | -5.00K | -11.00K | 3.00K | -44.00K |
| Operating Expenses | 84.99M | 60.30M | 35.25M | 22.21M | 24.14M |
| Cost & Expenses | 84.99M | 60.30M | 35.25M | 22.21M | 24.14M |
| Interest Income | 0.00 | 1.86M | 13.00K | 3.00 | 5.00 |
| Interest Expense | 0.00 | 0.00 | 13.00K | 3.00K | 5.00K |
| Depreciation & Amortization | 1.30M | 1.18M | 835.00K | 831.00K | 509.00K |
| EBITDA | -83.70M | -59.12M | -34.42M | -21.38M | -23.63M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -84.99M | -60.30M | -35.25M | -22.21M | -24.14M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.72M | 1.53M | -1.00K | 0.00 | -60.00K |
| Income Before Tax | -76.27M | -58.76M | -35.25M | -22.21M | -24.20M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 137.00K | -1.53M | -830.00K | 3.00K | 5.00K |
| Net Income | -76.41M | -57.23M | -34.42M | -22.21M | -24.21M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.93 | -1.91 | -1.18 | -0.76 | -0.83 |
| EPS Diluted | -1.93 | -1.91 | -1.18 | -0.76 | -0.83 |
| Weighted Avg Shares Out | 39.62M | 29.94M | 29.21M | 29.22M | 29.22M |
| Weighted Avg Shares Out (Dil) | 39.62M | 29.94M | 29.21M | 29.22M | 29.22M |
Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments
BOSTON--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the appointments of Jill Hopkins, M.D., as Chief Medical Officer, President of Research &...
Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
BOSTON--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial results for the second quarter ended June 30, 2023, and provided clinical development...
Aura Biosciences: Excellent Execution In The Large Ocular Cancer Market
AURA has solid phase 2 data for a very interesting molecule in primary choroidal melanoma. This indication has no approved therapies, no major pipeline development, and many US/EU patients.
Aura Biosciences to Participate in Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following...
Des orateurs de premier plan rehausseront de leur présence la conférence Kinexions 2023
OTTAWA, Ontario--(BUSINESS WIRE)--Mel Robbins, auteur favori du New York Times et célèbre animateur de podcast, et Kevin O’Marah, leader d’opinion de la chaîne d’approvisionnement et co-fondateur de Zero100, tiendront la vedette lors de Kinexions 2023, la Conférence des planificateurs et...
Alarm.com acquiert EBS, un fabricant polonais de dispositifs communicationnels de sécurité
TYSONS, Virginie--(BUSINESS WIRE)--Alarm.com (Nasdaq : ALRM) annonce avoir acquis EBS, spécialiste de la conception et de la fabrication de communicateurs intelligents largement déployés sur les marchés internationaux. Cette acquisition renforce les capacités d’Alarm.com dans la fourniture de technologies de sécurité...
Global Outdoor Furniture Market 2022 - 2030: Growing Real Estate Industry and Rising Urban Population Fuel the Sector - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Outdoor Furniture Market Size, Share & Trends Analysis Report By Material Type (Wood, Plastic, Metal), By End-use (Commercial, Residential), By Region (APAC, North America, Europe), And Segment Forecasts, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering....
Clarity AI : 44 % des investisseurs professionnels utilisent désormais des capacités d'analyse ou des données sur le développement durable provenant de plusieurs prestataires de services
NEW YORK--(BUSINESS WIRE)--44 % des investisseurs professionnels utilisent désormais des capacités d'analyse ou des données sur le développement durable provenant de plusieurs prestataires de services, ce qui suggère que les acteurs du marché recherchent un plus grand nombre de solutions...
ACTICOR BIOTECH : Compte rendu de l’Assemblée Générale Mixte du 12 mai 2023
PARIS--(BUSINESS WIRE)--Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 – ALACT), entreprise biopharmaceutique au stade clinique qui développe glenzocimab, un médicament innovant pour le traitement des urgences cardiovasculaires, notamment les accidents vasculaires cérébraux ischémiques, publie aujourd'hui le compte rendu de son Assemblée Générale...
La saison 2023 de la Coupe Nissan Sentra sera lancée les 27 et 28 mai prochains au Circuit Mont-Tremblant
MISSISSAUGA, Ontario--(BUSINESS WIRE)--C’est le samedi 27 mai prochain, sur le Circuit Mont-Tremblant au Québec, que sera présenté la première course 2023 de la Coupe Nissan Sentra. La populaire série canadienne de sport automobile débutera ainsi sa troisième année d’existence, la...
Source: https://incomestatements.info
Category: Stock Reports